Results 221 to 230 of about 938,133 (296)
Humoral immunity in cancer. [PDF]
Leonard J, Duhamel M, Salzet M.
europepmc +1 more source
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai +12 more
wiley +1 more source
IL18BP links antigen processing and presentation programs to a dendritic cell-enriched immunoregulatory state in colorectal cancer. [PDF]
Zheng J +9 more
europepmc +1 more source
A hierarchically selective immunotherapeutic nanoplatform, mGls@HEV‐MTP, selectively restores macrophage immunocompetence through GLS1‐mediated restoration of glutaminolysis‐fueled anaplerosis. Concurrently, it renders Staphylococcus aureus (S. aureus) more readily recognizable to the metabolically reprogrammed macrophages, thereby facilitating ...
Weinan Yang +17 more
wiley +1 more source
BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series. [PDF]
Takemura K +5 more
europepmc +1 more source
Compared to E8, mTeSR1 culture downregulated WNT and TGF‑β signaling, and upregulated neural differentiation pathways, enhancing neural priming. Under skin organoid induction conditions, mTeSR1‑cultured hESCs generated organoids with significantly higher neuroepithelial differentiation.
Zhongliang Chen +7 more
wiley +1 more source
In a nutshell: Pandora's Box-B-cell lymphoproliferation masking inborn errors of immunity. [PDF]
Sánchez-Ramón S, Bussel JB.
europepmc +1 more source
Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment
Trogocytosis efficiency varies significantly among different tumor cells and is inversely related to their cortical stiffness; this efficiency dictates the extent of immunosuppression via upregulation of CXCL5 and Arg‐1, ultimately driving CD8+T cell exhaustion and tumor escape.
Chao Liang +9 more
wiley +1 more source
Clinical and Molecular Features of BAP1-Mutated Meningiomas: Case Series. [PDF]
Pradilla I +7 more
europepmc +1 more source
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source

